Guardant Health (GH) Co-CEO Helmy Eltoukhy discloses December 2025 share sales

Rhea-AI Filing Summary

Guardant Health, Inc. Co-Chief Executive Officer and director Helmy Eltoukhy reported open-market sales of company stock. On 12/15/2025, he sold 83,945 shares of common stock at a weighted average price of $103.8012 per share, and an additional 6,620 shares at a weighted average price of $104.0224 per share. Both transactions are coded as sales. Following these trades, he beneficially owns 2,047,143 shares of Guardant Health common stock directly. The prices reflect multiple individual transactions within narrow price ranges, and detailed trade breakdowns are available upon request from the company or the reporting person.

Insider Trade Summary

Net Seller: 90,565 shares ($9,402,220)

Net Sell 2 txns

Insider Eltoukhy Helmy

Role Co-Chief Executive Officer

Sold 90,565 shs ($9.40M)

Type	Security	Shares	Price	Value
Sale	Common Stock	83,945	$103.8012	$8.71M
Sale	Common Stock	6,620	$104.0224	$689K

Holdings After Transaction: Common Stock — 2,053,763 shares (Direct)

Footnotes (1)

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.02 to $104.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.020 to $104.055. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eltoukhy Helmy

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		S		83,945	D	$103.8012(1)	2,053,763	D
Common Stock	12/15/2025		S		6,620	D	$104.0224(2)	2,047,143	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $103.02 to $104.01. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.020 to $104.055. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Helmy Eltoukhy	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Guardant Health (GH) report for Helmy Eltoukhy?

Guardant Health reported that Co-Chief Executive Officer and director Helmy Eltoukhy sold shares of the company’s common stock in open-market transactions on 12/15/2025.

How many Guardant Health (GH) shares did Helmy Eltoukhy sell on December 15, 2025?

On 12/15/2025, Helmy Eltoukhy sold 83,945 Guardant Health common shares in one set of transactions and 6,620 shares in another.

At what prices were Helmy Eltoukhy’s Guardant Health (GH) shares sold?

The 83,945 shares were sold at a weighted average price of $103.8012 per share, and the 6,620 shares were sold at a weighted average price of $104.0224 per share.

How many Guardant Health (GH) shares does Helmy Eltoukhy own after the reported sales?

After the reported transactions, Helmy Eltoukhy beneficially owns 2,047,143 shares of Guardant Health common stock directly.

Were Helmy Eltoukhy’s Guardant Health (GH) sales executed in multiple trades?

Yes. Each reported line reflects a weighted average sale price, with shares sold in multiple transactions within disclosed price ranges on 12/15/2025.

Can investors obtain detailed trade prices for Helmy Eltoukhy’s Guardant Health (GH) sales?

Yes. The reporting person has undertaken to provide to Guardant Health, regulators, or any security holder, upon request, full information on the number of shares sold at each separate price within the stated ranges.